NCT06050980View on ClinicalTrials.gov

Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation

PHASE1RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 27, 2023

Primary Completion Date

August 30, 2025

Study Completion Date

June 7, 2027

Conditions
NSCLC
Interventions
DRUG

HSK40118

Oral administration, QD

Trial Locations (12)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

110002

RECRUITING

The First Hospital of China Medical University, Shenyang

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

250117

RECRUITING

Shandong Cancer Hospital, Jinan

318050

RECRUITING

Taizhou hospital of Zhejiang Province, Taizhou

350000

RECRUITING

Fujian Cancer Hospital, Fuzhou

400000

RECRUITING

Chongqing Cancer Hospital, Chongqing

410031

RECRUITING

Hunan Cancer Hospital, Changsha

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

471000

RECRUITING

First Affiliated Hospital of Henan University of Science and Technology, Luoyang

530000

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY